the respondent is the producer of perindopril erbumine products are the generic version of coversyl.
1 the applicant is the owner of the therapeutic drug coversyl (active ingredient - perindopril) which has three registered indications for treatment: hypertension, chronic heart fatigue and coronary artery disease.
the applicant sought an interlocutory injunction preventing the respondent from representing that its products were substitutable with coversyl to treat coronary artery disease.